Health authorities in the U.S. are continuing their move away from animal testing in drug development, with the FDA signaling ...
Explore the latest developments showcased at World ADC, highlighting smarter payloads and precise targeting in drug discovery ...
Morning Overview on MSN
FDA urges alternatives to animal testing in early-stage drug development
The U.S. Food and Drug Administration is actively steering drug developers away from traditional animal studies and toward ...
Zacks Investment Research on MSN
OCGN gene-agnostic eye therapy could shift retinal drug development
Ocugen OCGN is building its ocular portfolio around a modifier gene therapy idea: instead of designing a therapy for a single ...
The Mystra platform, developed over 10 years, offers biopharma partners proven analytical power to turn months of R&D into minutes, dramatically increasing the availability of quality genetic insights ...
Find out how self-driving labs utilise data-driven approaches to enhance drug discovery efficiency and innovation.
Funding and clinical trial-based barriers must be addressed to ensure success on the path to developing a DMT for Parkinson’s ...
Cells face constant threats from inside and out. Thus, they’ve evolved sophisticated stress response pathways such as the unfolded protein response (UPR), ...
Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results